Compass Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vivo Opportunity Fund Holdings, L.P. and related entities have reported a beneficial ownership stake of 4.0% in Compass Therapeutics, Inc.
NASDAQ
State Street Corporation has disclosed beneficial ownership of 5.5% of Compass Therapeutics' common stock as of June 30, 2026.
NASDAQ
SCHEDULE 13G: BlackRock Discloses 5.2% Stake in Compass Therapeutics
BlackRock, Inc. has reported a 5.2% beneficial ownership stake in Compass Therapeutics, Inc. as of December 31, 2025, as disclosed in a Schedule 13G filing dated January 21, 2026.
NASDAQ
Vivo Opportunity Fund Holdings and its affiliates have disclosed a 5.1% passive beneficial ownership stake in Compass Therapeutics, Inc.
NASDAQ
Tang Capital Management and its affiliates have disclosed a 9.99% beneficial ownership stake in Compass Therapeutics, Inc., comprising common stock and exercisable warrants.
NASDAQ
Tang Capital Management and its affiliates have disclosed a 9.99% beneficial ownership stake in Compass Therapeutics, Inc., comprising common stock and exercisable warrants.
NASDAQ
A group of entities led by Mark N. Lampert, including Biotechnology Value Fund L.P., has reported a collective beneficial ownership of 5.1% in Compass Therapeutics, Inc.
NASDAQ
Suvretta Capital Management, Averill Master Fund, and Aaron Cowen have collectively reported significant beneficial ownership in Compass Therapeutics, Inc., with Suvretta and Cowen each holding 8.2% and Averill holding 7.1% of common stock.
NASDAQ
SCHEDULE 13G/A: Tang Capital Boosts Compass Therapeutics Stake to 9.8%
Tang Capital Management and affiliates report a 9.8% beneficial ownership in Compass Therapeutics, Inc., reserving the right for director nominations.
NASDAQ
RTW Investments and Roderick Wong filed an amended Schedule 13G to correct an administrative error, confirming they hold no shares in Compass Therapeutics, Inc.
NASDAQ
RTW Investments and Roderick Wong have increased their beneficial ownership in COMPASS Pathways plc to 9.9% through a passive investment.
NASDAQ
Suvretta Capital Management and its affiliates have disclosed a 5.2% beneficial ownership stake in Compass Therapeutics, Inc. common stock.
NASDAQ
MPM BioImpact LLC has reported a reduced beneficial ownership stake of 4.1% in Compass Therapeutics, Inc. common stock.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 4.6% Passive Stake in Compass Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.6% beneficial ownership stake in Compass Therapeutics, Inc. as of June 30, 2025.
NASDAQ
Tang Capital Management and its affiliates have filed an amended Schedule 13G, reporting a passive beneficial ownership of 8.0% in Compass Therapeutics, Inc., totaling 11,052,632 shares.
NASDAQ
MPM BioImpact LLC has filed a Schedule 13G, revealing a beneficial ownership of 6.2% of Compass Therapeutics, Inc.'s common stock as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Adage Capital Management Amends Passive Stake in Compass Therapeutics, Holding 4.36% of Common Stock
Adage Capital Management, L.P. and its principals, Robert Atchinson and Phillip Gross, have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.36% in Compass Therapeutics, Inc. as of December 31, 2024.
NASDAQ
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.0% beneficial ownership stake in Compass Therapeutics, Inc. as of December 31, 2024.
NASDAQ
Tang Capital Management, LLC and its affiliated entities, including Kevin Tang, have disclosed a beneficial ownership of 5.4% in Compass Therapeutics, Inc., totaling 7,400,000 shares.